Actively Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Led by Revolution Medicines, Inc. · Updated on 2025-11-12
754
Participants Needed
16
Research Sites
268 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
CONDITIONS
Official Title
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through DNA sequencing
- Pancreatic ductal adenocarcinoma with wild-type RAS (expansion)
- Treatment naive or previously treated with standard therapy appropriate for tumor type and stage
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Primary central nervous system tumors
- Active, untreated brain metastases
- Known or suspected impairment of gastrointestinal function that may prevent swallowing or absorption of oral medication
- History of unstable or clinically significant concurrent medical condition that could affect safety, expected survival, or ability to comply with the study protocol
- Other exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
UC Irvine/Chao Family Comprehensive Cancer Center
Orange, California, United States, 92868
Actively Recruiting
2
UCLA
Santa Monica, California, United States, 90404
Actively Recruiting
3
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
4
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
5
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
6
Perlmutter Cancer Center at NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
7
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Actively Recruiting
8
Columbia University
New York, New York, United States, 10032
Actively Recruiting
9
Christ Hospital Cancer Center
Cincinnati, Ohio, United States, 45219
Actively Recruiting
10
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
11
University of Texas at Austin
Austin, Texas, United States, 78712
Actively Recruiting
12
Mary Crowley Cancer Research
Dallas, Texas, United States, 75230
Actively Recruiting
13
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
14
Next Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
15
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Actively Recruiting
16
Next Oncology Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
R
Revolution Medicines, Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here